As part of a licensing agreement, BioCritica will acquire the US development and commercialization rights to Lilly's Xigris treatment for severe sepsis and the rights to potentially acquire several critical care compounds currently in pre-clinical development at Lilly.
New York-listed drugs company Eli Lilly has teamed up with venture capital firms Care Capital and NovaQuest Capital to form BioCritica to commercialise a medicine for blood poisoning.
As part of a licensing agreement, BioCritica will acquire the US development and commercialization rights to Lilly’s Xigris treatment for severe sepsis and the rights to potentially acquire several critical care compounds currently in pre-clinical development at Lilly.
In return, Lilly will receive royalties on future US sales of Xigris and…
